Principal Technologies (TSXV:PTEC)

Principal Technologies Announces Extension of Private Placement Closing Date

Principal Technologies Inc. (the "Company") (TSXV: PTEC; FSE: J07), announces that it has received an extension from the TSX Venture Exchange with respect to the duration of its previously announced private placement (the "Private Placement") (see the Company's press releases dated April 3, 2024; June 7, 2024; June 20, 2024; and June 24, 2024), and intends to close a second and final tranche of the Private Placement on or before August 16, 2024.

All securities issued to the Offering will be subject to a statutory four-month hold period. The closing of the second tranche of the Offering will be subject to a number of conditions, including without limitation, approval of the TSXV.

ON BEHALF OF THE BOARD

Jerry Trent, Chief Executive Officer

Principal Technologies Inc.

For investor inquiries or further information, please contact:

Office@principal-technologies.com

Forward-looking statements:

This press release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable securities laws. This information and statements address future activities, events, plans, developments and projections. All statements, other than statements of historical fact, constitute forward-looking statements or forward-looking information. Such forward-looking information and statements are frequently identified by words such as "may," "will," "should," "anticipate," "plan," "expect," "believe," "estimate," "intend" and similar terminology, and reflect assumptions, estimates, opinions and analysis made by management of the Company in light of its experience, current conditions, expectations of future developments and other factors which it believes to be reasonable and relevant.

Risks and uncertainties that may cause actual results to vary include but are not limited to the availability of financing; fluctuations in commodity prices; changes to and compliance with applicable laws and regulations, including environmental laws and obtaining requisite permits and approvals; political, economic and other risks; as well as other risks and uncertainties which are more fully described in our annual and quarterly Management's Discussion and Analysis and in other filings made by us with Canadian securities regulatory authorities and available at www.sedarplus.ca. The Company disclaims any obligation to update or revise any forward-looking information or statements except as may be required.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source

Click here to connect with Principal Technologies Inc. (TSXV: PTEC; FSE: J07), to receive an Investor Presentation

PTEC:CC
The Conversation (0)
PRINCIPAL TECHNOLOGIES ANNOUNCES CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT

PRINCIPAL TECHNOLOGIES ANNOUNCES CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT

Principal Technologies Inc. (the " Company ") (TSXV: PTEC) (FSE: J07), is pleased to announce the closing of the first tranche (" Tranche 1 ") of its previously announced non-brokered private placement (the " Offering ") with one investor, MRPT Invest UG (" MRPT "), a company owned and controlled by Markus Mair . The Company issued a total of 4,000,000 units at $0.25 per unit for gross proceeds of $1,000,000 . Each unit (a " Unit ") will consist of one common share (a ' Share ") of the Company and one common share purchase warrant (a " Warrant "). Each Warrant entitles the holder to purchase one additional Share of the Company at $0.30 for a period of two (2) years from the date of closing. The Warrants are subject to a blocker term that prohibits exercise of the Warrants to the extent the holder would as a result of any exercise exceed 19.99% of then issued Shares.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
PRINCIPAL TECHNOLOGIES ANNOUNCES UPSIZING OF PRIVATE PLACEMENT

PRINCIPAL TECHNOLOGIES ANNOUNCES UPSIZING OF PRIVATE PLACEMENT

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES /

Principal Technologies Inc. (the " Company ") (TSXV: PTEC) (FSE: J07), is pleased to announce an increase in the previously announced non-brokered financing of 4,000,000 units (see news release dated April 3, 2024 ), to 8,000,000 units at $0.25 (the " Offering Price ") for gross proceeds of up to $2,000,000 (the " Private Placement) . Each unit (a " Unit ") will consist of one common share (a " Share ") of the Company and one common share purchase warrant (a " Warrant "). Each Warrant entitles the holder to purchase one additional Share of the Company at $0.30 for a period of two (2) years from the date of closing. The Company has received $1,000,000 of subscriptions with funds being held in escrow. The closing of a first tranche is pending receipt of TSX Venture Exchange (" TSXV ") approval.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
PRINCIPAL TECHNOLOGIES ANNOUNCES LOAN FINANCING AND PRIVATE PLACEMENT AND PROVIDES UPDATE ON VIVOSTAT A/S ACQUISITION

PRINCIPAL TECHNOLOGIES ANNOUNCES LOAN FINANCING AND PRIVATE PLACEMENT AND PROVIDES UPDATE ON VIVOSTAT A/S ACQUISITION

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES /

Principal Technologies Inc. (the " Company ") (TSXV: PTEC) (FSE: J07), is pleased to announce that on March 8, 2024 it entered into a binding commitment letter with the effect that the GreenIslands Opportunities Fund (the " Lender ") will provide a secured loan in the principal amount of €8,000,000 (the " Loan ") to provide acquisition financing with respect to the cash portion of the purchase price for Vivostat AS (" Vivostat "), as further outlined in its news release dated February 6, 2024 and for general working capital purposes.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
PRINCIPAL TECHNOLOGIES ANNOUNCES FUNDAMENTAL ACQUISITION OF VIVOSTAT A/S

PRINCIPAL TECHNOLOGIES ANNOUNCES FUNDAMENTAL ACQUISITION OF VIVOSTAT A/S

/Not for distribution to U.S. news wire services or for dissemination in the United States /

  • Binding Share Purchase Agreement to purchase 100% of Denmark -based Vivostat A/S (" Vivostat ").
  • Vivostat has a unique system for on-site preparation and application of autologous concentrated fibrin and platelet enriched fibrin sealants for use in post-surgical procedures.
  • Used in over 200,000 surgical procedures, Vivostat's system has peer-reviewed evidence of zero rejection and infection rates.
  • Vivostat has been profitable for the last 3 years and currently generates revenues of approximately €3,600,000 per year with a 60% gross profit margin.
  • Vivostat is currently only actively marketed in six European countries representing less than 10% of its total addressable market.
  • Transaction is expected to close on or before March 15, 2024 , subject to receipt of applicable approvals, including of the TSX Venture Exchange (" TSX-V ") and satisfaction of conditions.

Principal Technologies Inc. (the " Company " or " Principal ") (TSXV: PTEC) (FSE: J07), is pleased to announce that as at February 6, 2024 it entered into an arm's length binding Share Purchase Agreement (" SPA ") to acquire (the " Acquisition ") 100% of the equity interests of Vivostat, a 23-year-old Danish company which uses a unique autologous fibrin sealant solution for post-surgical use.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
PRINCIPAL TECHNOLOGIES CLOSES THIRD AND FINAL TRANCHE OF OVERSUBSCRIBED PRIVATE PLACEMENT

PRINCIPAL TECHNOLOGIES CLOSES THIRD AND FINAL TRANCHE OF OVERSUBSCRIBED PRIVATE PLACEMENT

/Not for distribution to U.S. news wire services or for dissemination in the United States /

Principal Technologies Inc. (the " Company ") (TSXV: PTEC ), is pleased to announce the closing of the third and final tranche (" Tranche 3 ") of its previously announced non-brokered private placement (the " Offering "). The Company issued an additional 833,333 common shares (the " Shares ") at $0.15 per Share for gross proceeds of $124,999.95 bringing the total offering to 9,993,166 Shares for aggregate gross proceeds of $1,498,974.95 when combined with the two previous closings, subject to final approval from the TSX Venture Exchange (" TSXV "). For more information on the Offering, see the Company's news releases dated October 6, 2023 November 21, 2023 and December 21, 2023 .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

BMO Expands Canadian Depositary Receipt Lineup with 10 New Listings from Europe and Japan

BMO's CDRs offer enhanced portfolio diversification opportunities for Canadian investors enabling them to hold shares in international companies that trade on a Canadian exchange in Canadian dollars

Bank of Montreal (BMO) announced 10 new CDRs will begin trading on the Cboe Canada exchange today. The initial offering of these new CDRs has closed.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Two people wearing lab coats shake hands in business agreement.

What is In-Licensing?

When it comes to investing in pharmaceutical companies, looking at pipelines and research and development prospects is important. But in-licensing is also key when examining these stocks.

In fact, in-licensing deals might be the pharmaceutical industry’s preferred mode of business development these days — perhaps even more so than M&A activity. These agreements can prove to be very fruitful for companies and their share prices.

The in-licensing strategy is likewise attractive to investors, as in-licensing drugs expedites corporate development while also mitigating risk. So let’s clear up some common questions around the strategy. The article below runs through what it means to in-license a drug and how in-licensing differs from an acquisition. It also covers how royalties affect returns. It’s key for investors to be aware of these intricacies so that they can interpret a firm’s actions correctly and elect to buy or sell at the right time.

Keep reading...Show less
Test tubes.

Amgen, Merck and Pfizer Release Latest Quarterly Earnings, Share 2025 Plans

Earnings season is in full swing in the pharma sector with major players sharing their latest results.

On Tuesday (February 4), Amgen (NASDAQ:AMGN), Merck (NYSE:MRK) and Pfizer (NYSE:PFE) released financial results for the most recent quarter, providing critical data points for evaluating investment potential.

Keep reading...Show less
A variety of pills on top of US money.

Johnson & Johnson to Expand Neuroscience Portfolio with US$14.6 Billion Acquisition

Pharmaceutical giant Johnson & Johnson (J&J) (NYSE:JNJ) has announced plans to acquire Intra-Cellular Therapies (NASDAQ:ITCI) in a US$14.6 billion deal, marking the largest acquisition for the sector in over two years.

The purchase, which is expected to close later this year pending regulatory and shareholder approvals, will give J&J access to Intra-Cellular's portfolio of treatments for neuropsychiatric and neurodegenerative disorders.

This includes Caplyta (lumateperone), an oral therapy for schizophrenia and bipolar depression that has been approved by the US Food and Drug Administration. Net product sales for Caplyta came in at US$175.2 million in the Q3 2024, a 39 percent increase year-on-year, with Intra-Cellular raising its annual guidance to US$665 million to US$685 million.

Keep reading...Show less
Scientist with petri dish.

Pharma Market Forecast: Top Trends for Pharma in 2025

The pharmaceutical industry is poised for a dynamic year in 2025. A confluence of positive trends suggests a brighter outlook ahead after declining earnings in recent years.

According to ZS consultant Cody Powers, lower interest rates could increase investment in biopharma, boosting research and development (R&D) into promising new indications, mergers and acquisitions (M&A) and clinical trials.

Industry executives polled for Deloitte’s 2025 life science outlook anticipate revenue growth and margin expansion, leading to increased investment in key therapeutic areas such as oncology, immunology, neurology and, of course, treatments for obesity and diabetes. This renewed focus on innovation, coupled with a changing regulatory environment, is expected to drive interest in the sector that could reshape the competitive landscape.

Keep reading...Show less
Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

Top 5 Small-cap Pharma Stocks (Updated January 2025)

Today's pharmaceutical market is facing the challenges of inflation, government-imposed drug price caps and waning demand for COVID-19 vaccines. However, the industry's major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected to dissipate.

The US reigns supreme in the pharma market, both in terms of drug demand and development. In 2024, 50 novel medicines were approved by the US Food and Drug Administration (FDA), compared to 55 such approvals in 2023. Last year's FDA approvals include Eli Lilly and Company's (NYSE:LLY) Alzheimer's disease treatment Kisunla.

Big pharma largely stole the show in 2024, but some small- and mid-cap NASDAQ pharma stocks also made gains.

Keep reading...Show less

Latest Press Releases

Related News

×